38 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
8:00am
approval for this trial by a European agency. The Danish sites are experienced in conducting osteoarthritis studies with high recruitment rates and high
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
the recruitment of patients with higher levels of sepsis severity. Additionally, the amended protocol provides for two cohorts (treatment and placebo) rather … with the Company’s planned timeline for the initiation of recruitment as per the amended protocol,” stated Oren Hershkovitz, CEO of Enlivex. “Therefore
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
authority in Spain to open recruitment of patients in Spain into an ongoing Phase I/II clinical trial, evaluating Allocetra™ as monotherapy
6-K
EX-99.1
0wmnynm8w
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
6-K
EX-99.1
0nzx1e8
12 Sep 22
Report of Foreign Private Issuer
8:02am
6-K
EX-99.3
jd4nxhf 0389iijscrp
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
ruatql
17 Aug 22
Current Report
8:02am
6-K
EX-99.1
6wz8zbf1gg8qws
6 Jun 22
Report of Foreign Private Issuer
8:03am
6-K
EX-99.1
i57m6o
31 May 22
Report of Foreign Private Issuer
8:04am
6-K
EX-99.1
ps2zabx
9 May 22
Report of Foreign Private Issuer
9:10am
6-K
EX-99.1
22i3l
29 Apr 22
Report of Foreign Private Issuer
8:15am
6-K
EX-99.1
krews8yfj
22 Sep 21
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
rv102ts9 r99zgo
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
ro6ld
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.2
dacy8q1
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
424B5
jrajs9x9cyzsu7h
22 Oct 20
Prospectus supplement for primary offering
8:45am